In today’s briefing:
- Celltrion Inc (068270 KS): Sequentially Weak 1Q25 Result; Momentum to Accelerate in 2H
- LGND: 1Q:25 Results
- Incyte Corporation: Here Are The 5 Major Factors Propelling Our ‘Outperform’ Rating!
- Option Care Health Is Moving Infusion to Your Living Room—Can This Bold Bet Transform U.S. Healthcare?
- Tenet Healthcare’s $250M Acquisition Blitz Is Fueling a High-Acuity Revolution – What Lies Ahead?
- Kringle Pharma Inc (4884 JP): 1H FY09/25 flash update
- ENSGs Geographic Expansion And Improving Market Presence Is An Important Growth Lever!
Celltrion Inc (068270 KS): Sequentially Weak 1Q25 Result; Momentum to Accelerate in 2H
- Celltrion Inc (068270 KS) announced 1Q25 result, with revenue and operating profit decreasing 21% and 24%, QoQ, respectively. Net profit more than halved in 1Q25 compared with 4Q24.
- Sequential improvement in gross profit margin is one key positive highlight of 1Q25 result. Higher contribution of new products aided gross profit margin. This trend is expected to continue.
- Celltrion reaffirmed 2025 revenue guidance of KRW5T. Revenue is expected to be moderate in 1H25 and strong in the 2H25. Profitability improvement will be slower than expected earlier.
LGND: 1Q:25 Results
- Ligand Pharmaceuticals holds a portfolio of revenue, royalty & milestone generating assets that have been vetted by its internal investment team.
- Ligand considers individual biopharmaceutical products, platforms, companies & income streams in its opportunity set.
- It targets late-stage and commercial income-producing assets when making investments.
Incyte Corporation: Here Are The 5 Major Factors Propelling Our ‘Outperform’ Rating!
- Incyte’s first-quarter 2025 earnings report presents a mixed bag of results and outlooks, offering valuable insights for investors contemplating engagement with the company.
- Analyzing the financial performance, Incyte has demonstrated significant growth, reporting a 20% year-over-year increase in total revenues, reaching $1.05 billion.
- This is primarily driven by strong product revenue growth of 26%, benefitting from high demand for products such as Jakafi and Opzelura, along with the robust launch of Niktimvo.
Option Care Health Is Moving Infusion to Your Living Room—Can This Bold Bet Transform U.S. Healthcare?
- Option Care Health delivered a solid first quarter of 2025, with revenues rising by 16% over the year-ago quarter.
- The growth was well-balanced, with mid-teens expansion in acute therapies and high-teens growth in chronic therapies.
- The company capitalized on improved IV bag supply and continued investments in infrastructure to respond effectively to dynamic market demands.
Tenet Healthcare’s $250M Acquisition Blitz Is Fueling a High-Acuity Revolution – What Lies Ahead?
- Tenet Healthcare Corporation reported strong financial results for the first quarter of 2025, showcasing significant year-over-year growth in key financial metrics.
- The company’s net operating revenues reached $5.2 billion, with a consolidated adjusted EBITDA of $1.163 billion, representing a 14% growth from the previous year.
- The EBITDA margin also improved to 22.3%, a substantial 320 basis point increase, indicating improved operational efficiency and cost management.
Kringle Pharma Inc (4884 JP): 1H FY09/25 flash update
- Revenue and gross profit for 1H FY09/25 were JPY36mn, down 16.5% YoY, with SG&A expenses up 33.7%.
- Current assets decreased by JPY491mn, primarily due to a JPY427mn decline in cash and deposits from R&D expenses.
- Net assets fell by JPY499mn, mainly due to a net loss of JPY512mn, resulting in retained earnings at -JPY1.3bn.
ENSGs Geographic Expansion And Improving Market Presence Is An Important Growth Lever!
- The Ensign Group, Inc. reported a strong performance for the first quarter of fiscal year 2025, reflected in various all-time high metrics which illustrate its robust growth and operational efficiency.
- Key positives include substantial increases in both occupancy rates—same-store and transitioning operations reached 82.6% and 83.5%, respectively.
- Moreover, the company saw significant growth in skilled census and managed care census across its operations, driven by effective local leadership and improved clinical outcomes.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
